HER2 Support Group Forums - View Single Post - Ki67 Level 2 Weeks After Starting Arimidex Predicts Breast Cancer Relapse

Lani · 06-24-2006, 01:12 PM

Ki67 is a measurement of the proliferative rate of a tumor which is determined utilizing a sample of the tumor. It is not a blood test. This study involved neoadjuvant therapy, wherein they gave the treatment (arimidex in this case) BEFORE they did the definitive surgery. The Ki67 was determined on interval fine-needle biopsies DURING THE COURSE OF the treatment.

Neoadjuvant therapy has the advantage of giving information right away on whether the treatment is working or not. Adjuvant therapy given after definitive surgery and/or radiation leaves one guessing. Keep reading on---they are working on different tumor markers, different agents to use with PET and MRI to detect microscopic and small amounts of residual or recurrent disease.

Hope this helped!

06-24-2006, 01:12 PM	#3
Lani Senior Member Join Date: Mar 2006 Posts: 4,783	I think you are confused Ki67 is a measurement of the proliferative rate of a tumor which is determined utilizing a sample of the tumor. It is not a blood test. This study involved neoadjuvant therapy, wherein they gave the treatment (arimidex in this case) BEFORE they did the definitive surgery. The Ki67 was determined on interval fine-needle biopsies DURING THE COURSE OF the treatment. Neoadjuvant therapy has the advantage of giving information right away on whether the treatment is working or not. Adjuvant therapy given after definitive surgery and/or radiation leaves one guessing. Keep reading on---they are working on different tumor markers, different agents to use with PET and MRI to detect microscopic and small amounts of residual or recurrent disease. Hope this helped!